A medicine for belly fat in people with HIV; discussed for visceral fat.
iNot medical advice. We don’t recommend any dose. Every dose below is a quote from the person named, describing their views or their own use. Tesamorelin (Egrifta) is FDA-approved only for excess abdominal fat in people with HIV. It is not authorised in the EU (the application was withdrawn in 2012) and is prohibited by WADA.
10 statements from 7 people. Each one is word for word: we add punctuation only and mark cuts with […]. The chips repeat the exact words used.
“Tesamorelin dose: 1 mg right before bed yet 90 minutes after your last meal, and 1 mg upon waking yet ideally before exercise (via subcutaneous injection)”
Context: Part of the same injury stack. On his 2026 muscle-building protocol page he writes: “Tesamorelin is my go-to for elevating GH output”.
“Growth hormone secretagogues – for men and women UNDER 50. If you’re using Tesamorelin alone, take 1 mg in the AM and 1 mg in the PM.”
Context: From the “Recommended Doses” of his 2026 stack article. For people over 50 he recommends pharmaceutical growth hormone instead. He adds that he no longer recommends CJC-1295 “due to its side effect profile”. The article recommends products from BioLongevity Labs, a company he co-founded.
“and tesamorelin 1 milligram to 2 milligram subcutaneous up to three times daily”
Context: One line of his spoken GH cheat-sheet. He follows it with “that being said most people would use a growth hormone releasing hormone receptor agonist maybe once or twice per day in combination with a” ghrelin-receptor agonist.
“Tesamorelin is a bit more long-lasting than sermorelin and therefore is taken typically about three times per week, not five times per week.”
Context: Descriptive, comparing it with sermorelin. He gives no tesamorelin dose.
“Dosing Guidelines: 1mg 1–2x/day for 5 days per week for a 6–8 week cycle; OR 5mL of 1mg/0.6mL solution 1x/day, 6 days per week for a 6–8 week cycle. Administration Route: Subcutaneous injection. Timing Tips: Before bed, take it at least 90 minutes after eating. Upon waking, take tesamorelin ideally before exercise and eating.”
Context: Published as “Dosing Guidelines” in his recovery stack. Bullet points joined into one line.
“For muscle gain/fat loss, I’ve experienced the best results by taking tesamorelin in the morning before my fasted workout. But you can also take it before bed, at least 90 minutes after eating.”
Context: Own experience, from the timing tips of his muscle gain/fat-loss stack.
“The two that are different would be tesamorelin, ideal dose 2 milligrams per dose, which is 2,000 micrograms, so quite different.”
Context: Contrasting it with the 100 microgram amount he gives for ipamorelin, GHRP-6 and hexarelin. How often is not stated here. Elsewhere in the episode he describes a bedtime stack of BPC-157, ipamorelin and tesamorelin used with patients.
“Now, my experiments, don't copy these. I've used tesamorelin up to 2 milligrams a day, four to five to six times a week, never every day with these peptides. And I'm going to use this peptide for 16 to 30 to 40 weeks”
Context: Part of a visceral-fat stack with CJC-1295, ipamorelin, MOTS-c and retatrutide; he says he adds tesamorelin around week 16–24. Caption spelling of the compound name corrected: “Tesmearellin” → tesamorelin. He says in his videos that he is not a doctor.
“Typically, you want to start with something like a half a milligram, even one milligram subcutaneous injection five days a week, administered before your bedtime to align with your body's natural GH pulse.”
Context: From the tesamorelin entry of his fat-loss tier list (captioned “Tesmearellin”). In February 2026 he called “500 micrograms to 1 milligram daily” the “sweet spot”. He says in his videos that he is not a doctor.
“the FDA-labeled dose is around 1 to 2 mg daily. But, that 2 mg, I've never seen anybody take that off-label. In our clinic, we use different dosing and often a cycling schedule. Timing matters. We have patients take it away from meals, often in the evenings. Food, especially carbohydrates, will blunt the growth hormone release. So, an empty stomach helps maximize the goals. Think 1 mg at the most. 500 micrograms to 1,000 micrograms, 5 days on, 2 days off before bed.”
Context: What he says his clinic uses. In another video (N8fjEY1w45c, 8:03) he says the clinic gets results “with usually about a milligram, 1,000 micrograms”.
2 statements from 1 person about risks and how strong the evidence is.
“This goes by the brand name Egrifta and it's an FDA approved drug for the reduction of visceral adiposity in HIV patients.”
Context: His introduction to tesamorelin.
“If you're younger than 30, I don't know why you'd want to augment growth hormone unless you and your doctor decide that there's a clinical need or some other urgent need to do so because you're already making a lot of growth hormone. If you're older than 30 and you're interested in using these compounds, to me it stands to reason that of course you want to make sure that you don't have any tumors or cancers that you could potentially exacerbate. But in addition to that, that you really think about using the minimal effective dose and that you use perhaps even the mildest of these different compounds […]”
Context: Said in his closing summary on growth-hormone secretagogues as a group (sermorelin, tesamorelin, CJC-1295, ipamorelin and others), not about this compound alone.
Context, not a dosing guide. These are the conditions in published trials, all in people with HIV. They show what was tested for a specific medical use, not a dose for anyone else.
| Study | Studied in | What the study used | What it found |
|---|---|---|---|
| Falutz et al., 2007, N Engl J MedPubMed 18057338 | 412 adults with HIV and abdominal fat | 2 mg subcutaneously daily for 26 weeks | Visceral fat −15.2% vs +5.0% with placebo |
| Stanley et al., 2014, JAMAPubMed 25038357 | 50 adults with HIV | 2 mg daily for 6 months | Visceral fat and liver fat reduced vs placebo |
| Stanley et al., 2019, Lancet HIVPubMed 31611038 | 61 adults with HIV and fatty liver | 2 mg daily for 12 months | Hepatic fat fraction −4.1% (absolute) vs placebo; more injection-site complaints |
Yes, in the US (Egrifta, 2010) for reducing excess abdominal fat in adults with HIV. It is not authorised in the EU.
Both are GHRH analogues; tesamorelin is modified to last longer. Huberman’s comparison is quoted above.
No. WADA prohibits GHRH analogues.
We do not write our own dose ranges. The approved prescribing information is a matter for a doctor.
Word-for-word statements about how tesamorelin is used, each with a link to the source. Tesamorelin is an approved medicine in the US, and the trials behind that approval are listed separately as context.
Last reviewed 11 Oct 2026 · Compiled by the Peptide Dosing editorial team · How we check quotes